Home > Insider Trading > Filing (0001209191-23-043527)

Filing Details

Accession Number:: 0001209191-23-043527
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-07-27 16:23:01
Reporting Period:: 2023-07-25

Accepted Time:: 2023-07-27 16:23:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1764974	Turnstone Biologics Corp.	TSBX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1589095	Versant Affiliates Fund V, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1589097	Versant Venture Capital V, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1589098	Versant Ophthalmic Affiliates I, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1612235	Versant Venture Capital V (Canada), Lp	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1619297	Versant Ventures V Gp-Gp (Canada), Inc.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1619298	Versant Ventures V, Llc	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1716490	Versant Ventures V (Canada), L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1832235	Versant Vantage Ii, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1839789	Versant Vantage Ii Gp-Gp, Llc	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No
1839790	Versant Vantage Ii Gp, L.p.	One Sansome Street, Suite 1650 San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-07-25	2,528,864	$0.00	2,528,864	No	4	C	Indirect	By Versant Venture Capital V, L.P.
Common Stock	Acquisiton	2023-07-25	192,458	$0.00	192,458	No	4	C	Indirect	By Versant Venture Capital V (Canada) LP
Common Stock	Acquisiton	2023-07-25	84,313	$0.00	84,313	No	4	C	Indirect	By Versant Ophthalmic Affiliates Fund I, L.P.
Common Stock	Acquisiton	2023-07-25	76,067	$0.00	76,067	No	4	C	Indirect	By Versant Affiliates Fund V, L.P.
Common Stock	Acquisiton	2023-07-25	274,990	$0.00	274,990	No	4	C	Indirect	By Versant Vantage II, L.P.
Common Stock	Acquisiton	2023-07-25	197,458	$12.00	2,726,322	No	4	P	Indirect	By Versant Venture Capital V, L.P.
Common Stock	Acquisiton	2023-07-25	15,028	$12.00	207,486	No	4	P	Indirect	By Versant Venture Capital V (Canada) LP
Common Stock	Acquisiton	2023-07-25	6,575	$12.00	90,888	No	4	P	Indirect	By Versant Ophthalmic Affiliates Fund I, L.P.
Common Stock	Acquisiton	2023-07-25	5,939	$12.00	82,006	No	4	P	Indirect	By Versant Affiliates Fund V, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Versant Venture Capital V, L.P.
No	4	C	Indirect	By Versant Venture Capital V (Canada) LP
No	4	C	Indirect	By Versant Ophthalmic Affiliates Fund I, L.P.
No	4	C	Indirect	By Versant Affiliates Fund V, L.P.
No	4	C	Indirect	By Versant Vantage II, L.P.
No	4	P	Indirect	By Versant Venture Capital V, L.P.
No	4	P	Indirect	By Versant Venture Capital V (Canada) LP
No	4	P	Indirect	By Versant Ophthalmic Affiliates Fund I, L.P.
No	4	P	Indirect	By Versant Affiliates Fund V, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2023-07-25	7,897,999	$0.00	988,832	$0.00
Common Stock	Series A Preferred Stock	Disposition	2023-07-25	601,077	$0.00	75,255	$0.00
Common Stock	Series A Preferred Stock	Disposition	2023-07-25	263,349	$0.00	32,971	$0.00
Common Stock	Series A Preferred Stock	Disposition	2023-07-25	237,575	$0.00	29,744	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2023-07-25	3,530,789	$0.00	442,055	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2023-07-25	268,711	$0.00	33,642	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2023-07-25	117,730	$0.00	14,739	$0.00
Common Stock	Series B-1 Preferred Stock	Disposition	2023-07-25	106,208	$0.00	13,297	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2023-07-25	7,650,043	$0.00	957,787	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2023-07-25	582,206	$0.00	72,892	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2023-07-25	255,081	$0.00	31,936	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2023-07-25	230,117	$0.00	28,810	$0.00
Common Stock	Series C Preferred Stock	Disposition	2023-07-25	1,119,729	$0.00	140,190	$0.00
Common Stock	Series C Preferred Stock	Disposition	2023-07-25	85,217	$0.00	10,669	$0.00
Common Stock	Series C Preferred Stock	Disposition	2023-07-25	37,283	$0.00	4,667	$0.00
Common Stock	Series C Preferred Stock	Disposition	2023-07-25	33,682	$0.00	4,216	$0.00
Common Stock	Series D Preferred Stock	Disposition	2023-07-25	2,196,402	$0.00	274,990	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.
Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.